Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07834840
Enrolling by invitation Not applicable

Evaluation of the Impact of Dietary Education and Intervention on Gout Patients Receiving Urate-Lowering Therapy

NCT07834840 · tracked via the Priya Life Science South Korea tracker
Sponsor
Sung Keon Cho
Phase
Not applicable
Started
2025-03-26
Last updated
2026-09-22

Condition(s) studied

Gout DiseaseGout

Investigational drug(s) / intervention(s)

DASH DietLow-Uric acid Diet

DASH Diet: Participants will receive monthly reminders about dietary education and complete questionnaires to assess adherence to the assigned diet. * Every 6 months, participants will undergo measurements of body composition using bioelectrical impedance analysis, waist and hip circumference, and blood pressure during their scheduled outpatient visits to assess their health status. * Blood samples will be collected annually to assess the effects of the dietary intervention and education on participants' health. * Participants will receive KRW 40,000 in compensation for study participation every 12 months.

Low-Uric acid Diet: Participants will receive monthly reminders about dietary education and complete questionnaires to assess adherence to the assigned diet. * Every 6 months, participants will undergo measurements of body composition using bioelectrical impedance analysis, waist and hip circumference, and blood pressure during their scheduled outpatient visits to assess their health status. * Blood samples will be collected annually to assess the effects of the dietary intervention and education on participants' health. * Participants will receive KRW 40,000 in compensation for study participation every 12 months.

Study summary

The goal of this interventional study is to learn whether dietary education and intervention can reduce blood uric acid levels in patients with gout.

The main questions this study aims to answer are:

* Can dietary education and intervention reduce gout-related clinical laboratory results?
* Can dietary education and intervention improve BMI and SBP/DBP in participants with gout? In this study, participants will be divided into three groups, including a control group, and their outcomes compared, in order to determine whether a low-purine (low-uric-acid) diet and a DASH diet are effective in reducing blood uric acid levels in participants with gout.

Participants will:

* Participate in the study for a total of 2 years, receiving dietary education and intervention according to their assigned group throughout this period
* Complete surveys, physical measurements, and receive dietary education once every 6 months
* Receive dietary education by phone and through an app, and complete surveys, once every month

Eligibility

Sex
MALE
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Currently receiving urate-lowering therapy at this hospital 2. Male, aged 19 years or older, with a history of at least one gout flare Exclusion Criteria: 1. Unwilling or unable to provide informed consent 2. Life expectancy of less than 2years due to comorbid conditions 3. Refusal of urate-lowering therapy 4. Estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m² or less (diagnosed with chronic kidney disease stage 3B or higher) 5. E. Diagnosis of chronic obstructive pulmonary disease (COPD) or asthma within the past 6 months 6. F. History of gastrointestinal disease (including inflammatory bowel disease, malabsorption, gastric bypass surgery, or major bowel resection) 7. G. Currently receiving chemotherapy for cancer treatment 8. H. Diagnosis of myocardial infarction, heart failure, or angina, or history of coronary artery bypass surgery or angioplasty, within the past 6 months 9. I. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study

Primary outcome measure(s)

  • Uric Acid Level — Baseline, At 12-months, At 24-months
    Measured in serum

Trial sites (1)

FacilityCityRegionStatus
Ajou University Hospital Suwon Gyeonggi-do

Other trials for the same condition

the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07834840 on ClinicalTrials.gov ↗ ← All trials in South Korea